Hill Top Research positions itself for growth
companies in the US, has positioned itself for growth after last
week's acquisition by Utah's DW Healthcare Partners, a private
equity firm focused on the healthcare industry.
The acquisition, financed with $8 million in equity from >DWHP and additional debt financing from a third party provider, will allow Hill Top to expand capacity within the pharmaceutical services market, add new technical capabilities, and provide the funds for possible industry acquisitions, according to the company.
The new company will be called Hill Top Acquisition Corp. and will continue to do business as >Hill Top Research, offering a range of clinical research services, including safety testing, efficacy testing, sensory testing, claim substantiation, data management, project management, and microbiology.
"This investment enhances our ability to continue to offer clinical research expertise and subject recruiting at our multiple locations throughout North America. In addition, we can continue to invest in providing high quality clinical studies for our clients," said Joel Ivers, Hill Top COO.
In conjunction with the acquisition announcement, Hill Top also announced that its CEO of 20 years, Jim Pearce, has now retired and will be replaced by current COO Joel Ivers.
